1 Murata T, "Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels" 27 : 48-52, 1995
2 Freund KB, "Treat-andextend regimens with anti-vegf agents in retinal diseases : a literature review and consensus recommendations" 35 : 1489-1506, 2015
3 Silva R, "Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration : results with ranibizumab from the TREND Study" 125 : 57-65, 2018
4 Nguyen QD, "Ranibizumab for diabetic macular edema : results from 2 phase III randomized trials : RISE and RIDE" 119 : 789-801, 2012
5 Prunte C, "Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema:the RETAIN study" 100 : 787-795, 2016
6 Payne JF, "Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema : TREX-DME 1 year outcomes" 124 : 74-81, 2017
7 Pieramici D, "Outcomes of diabetic macular edema eyes with limited early response in the VISTA and VIVID studies" 2 : 558-566, 2018
8 Kim LN, "Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration" 36 : 1418-1431, 2016
9 Ip MS, "Long-term effects of ranibizumab on diabetic retinopathy severity and progression" 130 : 1145-1152, 2012
10 Korobelnik JF, "Intravitreal aflibercept for diabetic macular edema" 121 : 2247-2254, 2014
1 Murata T, "Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels" 27 : 48-52, 1995
2 Freund KB, "Treat-andextend regimens with anti-vegf agents in retinal diseases : a literature review and consensus recommendations" 35 : 1489-1506, 2015
3 Silva R, "Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration : results with ranibizumab from the TREND Study" 125 : 57-65, 2018
4 Nguyen QD, "Ranibizumab for diabetic macular edema : results from 2 phase III randomized trials : RISE and RIDE" 119 : 789-801, 2012
5 Prunte C, "Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema:the RETAIN study" 100 : 787-795, 2016
6 Payne JF, "Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema : TREX-DME 1 year outcomes" 124 : 74-81, 2017
7 Pieramici D, "Outcomes of diabetic macular edema eyes with limited early response in the VISTA and VIVID studies" 2 : 558-566, 2018
8 Kim LN, "Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration" 36 : 1418-1431, 2016
9 Ip MS, "Long-term effects of ranibizumab on diabetic retinopathy severity and progression" 130 : 1145-1152, 2012
10 Korobelnik JF, "Intravitreal aflibercept for diabetic macular edema" 121 : 2247-2254, 2014
11 Staurenghi G, "Impact of baseline diabetic retinopathy severity scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies" 102 : 954-958, 2018
12 "Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group" 98 : 786-806, 1991
13 Lanzetta P, "Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases" 255 : 1259-1273, 2017
14 Mitchell P, "Evaluating the impact of intravitreal aflibercept on diabetic retinopathy progression in the VIVID-DME and VISTA-DME studies" 2 : 988-996, 2018
15 Zhang Y, "Effects of aflibercept for neovascular age-related macular degeneration : a systematic review and meta-analysis of observational comparative studies" 58 : 5616-5627, 2017
16 Hirano T, "Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation" 61 : 51-60, 2017
17 Sugimoto M, "Clinical preferences and trends of anti-vascular endothelial growth factor treatments for diabetic macular edema in Japan" 10 : 475-483, 2019
18 Ashraf M, "Age-related macular degeneration : using morphological predictors to modify current treatment protocols" 96 : 120-133, 2018
19 Diabetic Retinopathy Clinical Research Network, "Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema" 372 : 1193-1203, 2015
20 Stewart MW, "Aflibercept(VEGF Trap-eye) : the newest anti-VEGF drug" 96 : 1157-1158, 2012
21 Kanda A, "Aflibercept traps galectin-1, an angiogenic factor associated with diabetic retinopathy" 5 : 17946-, 2015
22 Avitabile T, "Aflibercept in the treatment of diabetic macular edema : a review and consensus paper" 27 : 627-639, 2017
23 Chin-Yee D, "A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration" 100 : 914-917, 2016